The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples